Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to 0.73%.

  • InMed Pharmaceuticals' Return on Capital Employed rose 2900.0% to 0.73% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.73%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 0.67% for FY2025, which is 800.0% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Return on Capital Employed of 0.73% as of Q4 2025, which was up 2900.0% from 0.62% recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.52% for Q1 2024, and its period low was 1.73% during Q3 2022.
  • For the 4-year period, InMed Pharmaceuticals' Return on Capital Employed averaged around 0.92%, with its median value being 0.75% (2025).
  • As far as peak fluctuations go, InMed Pharmaceuticals' Return on Capital Employed surged by 10500bps in 2023, and later tumbled by -6400bps in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Return on Capital Employed (Quarter) stood at 1.19% in 2022, then soared by 49bps to 0.61% in 2023, then plummeted by -68bps to 1.02% in 2024, then grew by 29bps to 0.73% in 2025.
  • Its Return on Capital Employed stands at 0.73% for Q4 2025, versus 0.62% for Q3 2025 and 0.75% for Q2 2025.